Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Corn and Coconut Oils on Lipoprotein Lipids, Insulin Sensitivity and Inflammation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03202654
Recruitment Status : Completed
First Posted : June 28, 2017
Last Update Posted : May 15, 2018
Sponsor:
Collaborator:
ACH Food Companies, Inc.
Information provided by (Responsible Party):
Midwest Center for Metabolic and Cardiovascular Research

Brief Summary:
The objectives of this trial are to assess the effects of corn oil and coconut oil on low-density lipoprotein cholesterol (LDL-C) concentrations, and other aspects of the fasting lipoprotein lipid profile, as well as insulin sensitivity and an inflammatory marker, in men and women.

Condition or disease Intervention/treatment Phase
Healthy Men and Women Other: Corn Oil Other: Coconut Oil Not Applicable

Detailed Description:
This is a randomized, crossover, pilot study that includes two screening visits and two 4-week test periods, separated by a 3-week washout. Subjects will consume study products providing 4 tablespoons oil/day of either corn oil or coconut oil replacing the same amount of oil in the background diet. Subjects will otherwise be encouraged to follow their habitual diet during both treatment periods. They will receive diet instructions on the incorporation of food substitutions during the test periods to maintain habitual energy intake. Subjects will record daily study product intake and compliance in a Daily Log. An intravenous glucose tolerance test (IVGTT) will be completed at baseline and the end of each treatment period for evaluation of insulin sensitivity. Fasting blood samples will be collected for lipid profile and high-sensitivity C-reactive protein (hs-CRP) measurements at all visits. Assessments of vital signs and body weight, review of concomitant medication/supplement use and inclusion and exclusion criteria for relevant changes, and evaluation of adverse effects will be performed throughout the study. Compliance will be assessed using the Daily Log intake percentages as the primary source.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Supportive Care
Official Title: A Randomized, Double-Blind, Controlled, Crossover, Pilot Trial Comparing the Effects of Corn and Coconut Oils on Fasting Lipoprotein Lipids and Markers of Insulin Sensitivity and Inflammation in Men and Women
Actual Study Start Date : June 22, 2017
Actual Primary Completion Date : October 10, 2017
Actual Study Completion Date : October 31, 2017

Resource links provided by the National Library of Medicine

Drug Information available for: Corn oil

Arm Intervention/treatment
Experimental: Corn Oil Intervention
Study products delivering 4 tablespoons/day corn oil will be administered for 4-week treatment period.
Other: Corn Oil
4 tablespoons/day of corn oil for 4-week treatment period.

Active Comparator: Coconut Oil Intervention
Study products delivering 4 tablespoons/day coconut oil will be administered for 4-week treatment period.
Other: Coconut Oil
4 tablespoons/day of coconut oil for 4-week treatment period.




Primary Outcome Measures :
  1. Percent change in LDL-C [ Time Frame: Up to 28 days for each treatment period. ]
    Percent change in LDL-C from baseline (average of the values from one screening visit and the baseline visit) to the end of each test condition (average of the values at 2-week and 4-week visits of each test period).


Secondary Outcome Measures :
  1. Percent change in non-high-density lipoprotein cholesterol (Non-HDL-C). [ Time Frame: Up to 28 days for each treatment period. ]
    Percent change in Non-HDL-C from baseline (average of the values from one screening visit and the baseline visit) to the end of each test condition (average of the values at 2-week and 4-week visits of each test period).

  2. Percent change in Total Cholesterol (TC) [ Time Frame: Up to 28 days for each treatment period. ]
    Percent change in TC from baseline (average of the values from one screening visit and the baseline visit) to the end of each test condition (average of the values at 2-week and 4-week visits of each test period).


Other Outcome Measures:
  1. Percent change in Triglycerides (TG) [ Time Frame: Up to 28 days for each treatment period. ]
    Percent change in TG from baseline (average of the values from one screening visit and the baseline visit) to the end of each test condition (average of the values at 2-week and 4-week visits of each test period).

  2. Percent change in high-density lipoprotein cholesterol (HDL-C). [ Time Frame: Up to 28 days for each treatment period. ]
    Percent change in HDL-C from baseline (average of the values from one screening visit and the baseline visit) to the end of each test condition (average of the values at 2-week and 4-week visits of each test period).

  3. Percent change in TC/ (HDL-C) ratio. [ Time Frame: Up to 28 days for each treatment period. ]
    Percent change in TC/ HDL-C ratio from baseline (average of the values from one screening visit and the baseline visit) to the end of each test condition (average of the values at 2-week and 4-week visits of each test period).

  4. Disposition index [acute insulin response to intravenous glucose (AIRg) x IV-SI] [ Time Frame: Up to 50 minutes - measured at baseline, and end of each treatment period. ]
    Percent change (or change) from baseline to the end of each treatment period.

  5. Glucose fractional disappearance rate from t = 10-50 min (Kg) [ Time Frame: Up to 50 minutes - measured at baseline, and end of each treatment period. ]
    Percent change (or change) from baseline to the end of each treatment period.

  6. Homeostasis model assessments of insulin sensitivity (HOMA%S) [ Time Frame: Up to 28 days of each treatment period. ]
    Percent change or change from baseline to end of each treatment condition.

  7. Beta-cell function (HOMA%B) [ Time Frame: Up to 28 days of each treatment period. ]
    Percent change or change from baseline to end of each treatment condition.

  8. Insulin sensitivity index (IV-SI) [ Time Frame: Up to 50 minutes - measured at baseline, and end of each treatment period. ]
    Percent change or change from baseline to end of each treatment condition.

  9. Percent change in high-sensitivity C-reactive protein (hs-CRP) [ Time Frame: Up to 28 days for each treatment period. ]
    Percent change in hs-CRP from baseline (average of the values from one screening visit and the baseline visit) to the end of each test condition (average of the values at 2-week and 4-week visits of each test period).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 79 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. BMI of 18.5-34.9 kg/m2.
  2. Fasting LDL-C level ≥115 mg/dL and <190 mg/dL, and TG level ≤375 mg/dL.
  3. Judged to be in general good health on the basis of medical history and screening laboratory tests.

Exclusion Criteria:

  1. Atherosclerotic cardiovascular disease including any of the following:

    clinical signs of atherosclerosis including peripheral arterial disease, abdominal aortic aneurysm, carotid artery disease [symptomatic (e.g., myocardial infarction, angina, transient ischemic attack or stroke of carotid origin) or >50% stenosis on angiography or ultrasound] or other forms of clinical atherosclerotic disease (e.g., renal artery disease).

  2. History or presence of clinically important pulmonary (including uncontrolled asthma), endocrine (including type 1 or 2 diabetes mellitus), chronic inflammatory disease (including irritable bowel disease, lupus, rheumatoid arthritis), hepatic, renal, hematologic, immunologic, dermatologic, neurologic, psychiatric, or biliary disorders.
  3. Known allergy, sensitivity, or intolerance to any ingredients in the study products.
  4. Uncontrolled hypertension.
  5. Recent history of cancer, except for non-melanoma skin cancer.
  6. Recent change in body weight of ± 4.5 kg.
  7. Recent use of any medications intended to alter the lipid profile [e.g., statins, bile acid sequestrants, cholesterol absorption inhibitor, fibrates, niacin (drug form), omega-3-ethyl ester drugs, or proprotein convertase subtilisin kexin type 9 inhibitors].
  8. Recent use of any foods or dietary supplement that might alter lipid metabolism [e.g., omega-3 fatty acid supplements (e.g., flaxseed, fish or algal oils) or fortified foods, sterol/stanol products; dietary supplements (including Metamucil® or viscous fiber-containing supplement); red rice yeast supplements; garlic supplements; soy isoflavone supplements; niacin or its analogues at doses >400 mg/d].
  9. Recent use of weight-loss drugs or programs or antibiotics.
  10. Recent daily use of non-steroidal anti-inflammatory drugs (except low-dose aspirin) or unstable use of antihypertensive medication.
  11. Recent use of medications that influence carbohydrate metabolism (e.g., adrenergic receptor blockers, diuretics, hypoglycemic medications, and/or systemic corticosteroids).
  12. Pregnant, planning to be pregnant during the study period, lactating, or of childbearing potential and unwilling to commit to the use of a medically approved form of contraception throughout the study period.
  13. Extreme dietary habits (e.g., vegan or very low carbohydrate diet).
  14. Current or recent history for drug or alcohol abuse.
  15. History of a diagnosed eating disorder (e.g., anorexia or bulimia nervosa).
  16. Exposure to any non-registered drug product.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03202654


Locations
Layout table for location information
United States, Florida
MB Clinical Research
Boca Raton, Florida, United States, 33487
United States, Illinois
Great Lakes Clinical Trials
Chicago, Illinois, United States, 60640
Sponsors and Collaborators
Midwest Center for Metabolic and Cardiovascular Research
ACH Food Companies, Inc.
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Midwest Center for Metabolic and Cardiovascular Research
ClinicalTrials.gov Identifier: NCT03202654    
Other Study ID Numbers: MB-1703
First Posted: June 28, 2017    Key Record Dates
Last Update Posted: May 15, 2018
Last Verified: May 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Insulin Resistance
Inflammation
Pathologic Processes
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases